BCRX

8.29

0.96% -0.08

Pre-mercato: 8.40 0.11 +1.33%

Biocryst Pharmaceuticals Inc (BCRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BCRX Giù? Forum Previsione

Precedente Chiudi:

$8.37

Aprire:

$8.35

Volume 24 ore:

4.15M

Relative Volume:

0.77

Capitalizzazione di mercato:

$2.11B

Reddito:

$874.84M

Utile/perdita netta:

$263.86M

Rapporto P/E:

6.8905

EPS:

1.2031

Flusso di cassa netto:

$327.41M

1 W Prestazione:

-8.09%

1M Prestazione:

-7.99%

6M Prestazione:

+18.94%

1 anno Prestazione:

-20.21%

Intervallo 1D:

$8.215

$8.54

Intervallo di 1 settimana:

$8.215

$9.07

Portata 52W:

$6.00

$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Nome

Biocryst Pharmaceuticals Inc

Settore

Healthcare (1106)

Industria

Drug Manufacturers - Specialty & Generic (86)

Telefono

919-859-1302

Indirizzo

4505 EMPEROR BOULEVARD, DURHAM, NC

Dipendente

435

Cinguettio

@biocrystpharma

Prossima data di guadagno

2026-05-06

Ultimi documenti SEC

BCRX's Discussions on Twitter

Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BCRX Biocryst Pharmaceuticals Inc	8.29	2.13B	874.84M	263.86M	327.41M	1.2031
TAK Takeda Pharmaceutical Co Adr	16.25	52.07B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.29	41.28B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.07	39.78B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	81.32	33.57B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	568.43	24.02B	3.17B	1.29B	1.01B	27.09

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-18	Ripresa	Evercore ISI	Outperform
2025-10-15	Ripresa	TD Cowen	Buy
2025-10-01	Downgrade	Evercore ISI	Outperform → In-line
2025-04-29	Iniziato	Cantor Fitzgerald	Overweight
2025-02-25	Iniziato	Wedbush	Outperform
2023-11-20	Ripresa	JP Morgan	Overweight
2023-09-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-08-04	Aggiornamento	Jefferies	Hold → Buy
2023-07-13	Aggiornamento	BofA Securities	Neutral → Buy
2023-02-22	Aggiornamento	Needham	Hold → Buy
2022-11-02	Aggiornamento	Evercore ISI	In-line → Outperform
2022-08-05	Downgrade	Evercore ISI	Outperform → In-line
2022-08-05	Downgrade	Oppenheimer	Outperform → Perform
2022-04-18	Downgrade	Barclays	Overweight → Equal Weight
2022-04-11	Downgrade	BofA Securities	Buy → Neutral
2021-12-10	Iniziato	Oppenheimer	Outperform
2021-08-06	Downgrade	Jefferies	Buy → Hold
2021-08-03	Iniziato	Cantor Fitzgerald	Overweight
2021-03-01	Iniziato	Cowen	Outperform
2020-09-29	Ripresa	JP Morgan	Overweight
2020-06-17	Iniziato	BTIG Research	Neutral
2020-05-05	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-15	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-11-16	Ripresa	Piper Jaffray	Overweight
2018-08-08	Ripresa	JP Morgan	Overweight
2018-07-17	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-06-22	Iniziato	Seaport Global Securities	Neutral
2018-01-02	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2017-12-20	Iniziato	Barclays	Equal Weight
2017-09-15	Iniziato	RBC Capital Mkts	Sector Perform
2017-09-06	Aggiornamento	JP Morgan	Neutral → Overweight
2017-09-06	Aggiornamento	Jefferies	Hold → Buy
2017-02-16	Iniziato	Ladenburg Thalmann	Buy
2016-08-12	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-08-04	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Reiterato	FBR Capital	Outperform
2016-02-09	Downgrade	JP Morgan	Overweight → Neutral
2016-02-09	Downgrade	Needham	Buy → Hold

Mostra tutto

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

May 24, 2026

BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth from pediatric expansion - Investing.com Nigeria

May 24, 2026

May 23, 2026

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm

May 23, 2026

May 22, 2026

BioCryst director Amy McKee sells $100,284 in company shares By Investing.com - Investing.com South Africa

May 19, 2026

Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97 - Stock Titan

May 19, 2026

Biocryst’s BCX-17725 as new approach for Netherton syndrome - BioWorld News

May 19, 2026

Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - Yahoo Finance

May 19, 2026

May 18, 2026

BCRX (NASDAQ) Form 144: Affiliate plans resale of 11,180 shares - Stock Titan

May 18, 2026

BioCryst’s SWOT analysis: rare disease stock eyes growth path By Investing.com - Investing.com Nigeria

May 18, 2026

BioCryst’s SWOT analysis: rare disease stock eyes growth path - Investing.com

May 18, 2026

BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth beyond single product - Investing.com

May 18, 2026

BioCryst Pharmaceuticals’ SWOT analysis: stock gains ground on pediatric approval - Investing.com Nigeria

May 18, 2026

BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability - Investing.com UK

May 18, 2026

BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability By Investing.com - Investing.com Nigeria

May 18, 2026

BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path By Investing.com - Investing.com Australia

May 18, 2026

BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path - Investing.com

May 18, 2026

Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits

May 18, 2026

May 17, 2026

Responsive Playbooks and the BCRX Inflection - Stock Traders Daily

May 17, 2026

European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst (BCRX) - Sahm

May 17, 2026

May 16, 2026